Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.13 is 54% above its 5-year average of -2.43, near the high end of its 5-year range (-3.74–-1.13).
49.55% above its 12-month average of -2.24.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.13.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 26 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.13
EARNINGS PER SHARE (EPS) AVG TTM
-2.24
EARNINGS PER SHARE (EPS) AVG 3Y
-2.81
EARNINGS PER SHARE (EPS) AVG 5Y
-2.43
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+49.55%
CURRENT VS 3Y AVG
+59.82%
CURRENT VS 5Y AVG
+53.56%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ALX Oncology Holdings Inc.
Market Cap
$160.13M
Earnings Per Share (EPS)
-1.13
TTM Avg
-2.24
3Y Avg
-2.81
5Y Avg
-2.43
Market Cap
$160.82M
Earnings Per Share (EPS)
-0.90
TTM Avg
-1.19
3Y Avg
-2.61
5Y Avg
-1.83
Market Cap
$155.88M
Earnings Per Share (EPS)
-0.51
TTM Avg
-0.38
3Y Avg
-0.76
5Y Avg
-1.59
Market Cap
$154.57M
Earnings Per Share (EPS)
-1.64
TTM Avg
-1.85
3Y Avg
-1.46
5Y Avg
-1.46
Market Cap
$172.99M
Earnings Per Share (EPS)
-0.41
TTM Avg
-0.39
3Y Avg
-0.36
5Y Avg
-0.55
Market Cap
$173.04M
Earnings Per Share (EPS)
-1.02
TTM Avg
-0.60
3Y Avg
-1.87
5Y Avg
-1.57
Market Cap
$153.84M
Earnings Per Share (EPS)
-0.26
TTM Avg
-0.53
3Y Avg
-0.57
5Y Avg
-0.55
Market Cap
$152.16M
Earnings Per Share (EPS)
-0.26
TTM Avg
-0.32
3Y Avg
-0.33
5Y Avg
-0.37
Market Cap
$174.17M
Earnings Per Share (EPS)
-2.80
TTM Avg
-1.25
3Y Avg
-14.14
5Y Avg
-22.50
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ALX Oncology Holdings Inc. (ALXO) | $160.13M | -1.13 | -2.24 | -2.81 | -2.43 |
| Inogen, Inc. (INGN)vs › | $160.82M | -0.90 | -1.19 | -2.61 | -1.83 |
| LifeMD, Inc. (LFMDP)vs › | $155.88M | -0.51 | -0.38 | -0.76 | -1.59 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $154.57M | -1.64 | -1.85 | -1.46 | -1.46 |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.99M | -0.41 | -0.39 | -0.36 | -0.55 |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | -1.02 | -0.60 | -1.87 | -1.57 |
| Anavex Life Sciences Corp. (AVXL)vs › | $153.84M | -0.26 | -0.53 | -0.57 | -0.55 |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.16M | -0.26 | -0.32 | -0.33 | -0.37 |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | -2.80 | -1.25 | -14.14 | -22.50 |
| Codexis, Inc. (CDXS)vs › | $149.51M | -0.34 | -0.70 | -0.76 | -0.63 |
Trailing EPS (TTM)
$-1.13
Forward EPS (Est.)
$-0.56
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.90 |
| 2024-12-31 | -2.58 |
| 2023-12-31 | -3.74 |
| 2022-12-31 | -3.03 |
| 2021-12-31 | -2.07 |
| 2020-12-31 | -1.28 |
| 2019-12-31 | -0.88 |
| 2018-12-31 | -0.79 |
